Uisuk Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Uisuk Kim has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jaekyung Bae
Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea
5 shared publications - Myong Cheol Lim
Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea
5 shared publications - Ji Hyun Kim
Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea
4 shared publications - Sang-Yoon Park
Center for Gynecologic Cancer National Cancer Center Goyang Republic of Korea
3 shared publications - Chan-Wook Park
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Jeesun Lee
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Treatment patterns and survival outcomes according to histologic subtype in malignant ovarian germ cell tumors: a nationwide real-world cohort study
Bae J, et al. J Gynecol Oncol. 2026 Feb;37:e60. https://doi.org/10.3802/jgo.2026.37.e60
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Open AccessTreatment patterns and survival outcomes according to histologic subtype in malignant ovarian germ cell tumors: a nationwide real-world cohort study
Bae J, et al. J Gynecol Oncol. 2026 Feb;37:e60. https://doi.org/10.3802/jgo.2026.37.e60
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Prognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028)
Kim U, et al. J Gynecol Oncol. 2026 Jan;37:e59. https://doi.org/10.3802/jgo.2026.37.e59
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (3)
Open AccessPrognostic value and adjuvant treatment outcomes for the use of the JGOG prognostic model in early-stage intermediate-risk cervical cancer: a Korean Gynecologic Oncology Group study (KGOG 1028)
Kim U, et al. J Gynecol Oncol. 2026 Jan;37:e59. https://doi.org/10.3802/jgo.2026.37.e59
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Efficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification
Kim JH, et al. J Gynecol Oncol. 2025 Aug;37:e9. https://doi.org/10.3802/jgo.2026.37.e9
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Open AccessEfficacy and toxicity of PARP inhibitor in elderly patients with homologous recombination-deficient newly diagnosed advanced ovarian cancer: the role of dose modification
Kim JH, et al. J Gynecol Oncol. 2025 Aug;37:e9. https://doi.org/10.3802/jgo.2026.37.e9
- Open Access
Influence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis
Objective: While PARP inhibitors (PARPi) improve progression-free survival (PFS) in advanced ovarian cancer, their efficacy across different surgical outcomes is unclear. We aimed to determine if the efficacy of PARPi maintenance therapy, as measured by PFS, is modified by postoperative residual disease (R0 vs. R1/R2) in newly diagnosed advanced epithelial ovarian cancer. Methods: A systematic review and trial-level meta analysis of randomized controlled trials published through July 2025 was conducted. The primary endpoint was pooled hazard ratio (HR) for PFS, with subgroup analyses based on residual disease (R0 vs. R1/R2), clinical risk (higher risk vs. lower risk), and timing of surgery (primary cytoreductive surgery vs. interval cytoreductive surgery). Results: Six randomized controlled trials involving 3629 patients were included in this meta analysis. PARPi maintenance significantly improved PFS in both patients with no gross residual disease (R0) (HR 0.55, 95% CI 0.44–0.68, I2 = 64.2%) and those with macroscopic residual disease (R1/R2) (HR 0.51, 95% CI 0.40–0.65, I2 = 56.0%). The treatment effect did not differ significantly between these subgroups (p = 0.66). A numerically greater benefit was observed in lower-risk populations (HR 0.40, 95% CI 0.29–0.55, I2 = 0.9%) compared to higher-risk populations (HR 0.51, 95% CI 0.36–0.73, I2 = 78.5%, p = 0.30). The benefit was maintained irrespective of surgical timing, with similar pooled HRs for patients undergoing primary (HR 0.56, 95% CI 0.42–0.74, I2 = 72.3%) versus interval (HR 0.54, 95% CI 0.45–0.66, I2 = 44.2%) cytoreductive surgery. Conclusions: PARP inhibitor maintenance therapy provides a significant PFS benefit regardless of residual disease status, supporting its use in all eligible patients. Complete cytoreduction, however, remains crucial, as it provides the best foundation for achieving optimal long-term outcomes and maximizing the benefits of maintenance therapy.
Open AccessInfluence of Residual Disease on the Efficacy of PARP Inhibitors in Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta Analysis
Objective: While PARP inhibitors (PARPi) improve progression-free survival (PFS) in advanced ovarian cancer, their efficacy across different surgical outcomes is unclear. We aimed to determine if the efficacy of PARPi maintenance therapy, as measured by PFS, is modified by postoperative residual disease (R0 vs. R1/R2) in newly diagnosed advanced epithelial ovarian cancer. Methods: A systematic review and trial-level meta analysis of randomized controlled trials published through July 2025 was conducted. The primary endpoint was pooled hazard ratio (HR) for PFS, with subgroup analyses based on residual disease (R0 vs. R1/R2), clinical risk (higher risk vs. lower risk), and timing of surgery (primary cytoreductive surgery vs. interval cytoreductive surgery). Results: Six randomized controlled trials involving 3629 patients were included in this meta analysis. PARPi maintenance significantly improved PFS in both patients with no gross residual disease (R0) (HR 0.55, 95% CI 0.44–0.68, I2 = 64.2%) and those with macroscopic residual disease (R1/R2) (HR 0.51, 95% CI 0.40–0.65, I2 = 56.0%). The treatment effect did not differ significantly between these subgroups (p = 0.66). A numerically greater benefit was observed in lower-risk populations (HR 0.40, 95% CI 0.29–0.55, I2 = 0.9%) compared to higher-risk populations (HR 0.51, 95% CI 0.36–0.73, I2 = 78.5%, p = 0.30). The benefit was maintained irrespective of surgical timing, with similar pooled HRs for patients undergoing primary (HR 0.56, 95% CI 0.42–0.74, I2 = 72.3%) versus interval (HR 0.54, 95% CI 0.45–0.66, I2 = 44.2%) cytoreductive surgery. Conclusions: PARP inhibitor maintenance therapy provides a significant PFS benefit regardless of residual disease status, supporting its use in all eligible patients. Complete cytoreduction, however, remains crucial, as it provides the best foundation for achieving optimal long-term outcomes and maximizing the benefits of maintenance therapy.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (31) , e179
Impact of Clostridium difficile Infection on Chemotherapy in Patients With Primary Ovarian Cancer
Bae J, et al. J Korean Med Sci. 2025 Jun;40:e179. https://doi.org/10.3346/jkms.2025.40.e179
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (31) , e179
Open AccessImpact of Clostridium difficile Infection on Chemotherapy in Patients With Primary Ovarian Cancer
Bae J, et al. J Korean Med Sci. 2025 Jun;40:e179. https://doi.org/10.3346/jkms.2025.40.e179
- Open Access
Left Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer
The objective of this study is to investigate the surgical, clinical and pathological outcomes of left hemi-hepatectomy during cytoreductive surgery (CRS) in patients with primary ovarian cancer. The electronic medical charts of patients with primary ovarian cancer who received CRS including left hemi-hepatectomy from 2000 to 2023 were reviewed and retrospectively analyzed. A total of 17 patients underwent left hemi-hepatectomy for resection of a deep peritoneal implant in the round ligament of the liver during primary CRS. Among these 17 patients, hepatic parenchymal invasion was confirmed in 10 patients (58.8%). Tumor distribution of others is as follows: Glisson’s capsule, hilum, falciform ligament and gall bladder. Fourteen patients (82.4%) achieved CRS; the remaining three patients had residual tumors less than 1 cm. The median period to subsequent chemotherapy was 21 days (range, 12–35 days). No specific complications related to left hepatectomy were identified such as liver failure or bile leakage. Left hemi-hepatectomy for complete surgical resection of a deep peritoneal implant of the round ligament of the liver is surgically feasible and safe.
Open AccessLeft Hemi-Hepatectomy to Resect Metastatic Tumor of Round Ligament of Liver in Patients with Ovarian Cancer
The objective of this study is to investigate the surgical, clinical and pathological outcomes of left hemi-hepatectomy during cytoreductive surgery (CRS) in patients with primary ovarian cancer. The electronic medical charts of patients with primary ovarian cancer who received CRS including left hemi-hepatectomy from 2000 to 2023 were reviewed and retrospectively analyzed. A total of 17 patients underwent left hemi-hepatectomy for resection of a deep peritoneal implant in the round ligament of the liver during primary CRS. Among these 17 patients, hepatic parenchymal invasion was confirmed in 10 patients (58.8%). Tumor distribution of others is as follows: Glisson’s capsule, hilum, falciform ligament and gall bladder. Fourteen patients (82.4%) achieved CRS; the remaining three patients had residual tumors less than 1 cm. The median period to subsequent chemotherapy was 21 days (range, 12–35 days). No specific complications related to left hepatectomy were identified such as liver failure or bile leakage. Left hemi-hepatectomy for complete surgical resection of a deep peritoneal implant of the round ligament of the liver is surgically feasible and safe.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (8) , e70
Chromosomal Microarray Analysis in Fetuses With Ultrasonographic Soft Markers: A Meta-Analysis of the Current Evidence
Kim U, et al. J Korean Med Sci. 2024 Feb;39:e70. https://doi.org/10.3346/jkms.2024.39.e70
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (8) , e70
Open AccessChromosomal Microarray Analysis in Fetuses With Ultrasonographic Soft Markers: A Meta-Analysis of the Current Evidence
Kim U, et al. J Korean Med Sci. 2024 Feb;39:e70. https://doi.org/10.3346/jkms.2024.39.e70
- Open Access
- 1 January 2023
- Published by XMLink in Perinatology
- Vol. 34 (1) , 9-15
Association between Metabolic Syndrome at First Trimester and Adverse Pregnancy Outcome: A Cohort Study
Bae JH, et al. Perinatology. 2023 Mar;34(1):9-15. https://doi.org/10.14734/PN.2023.34.1.9
- 1 January 2023
- Published by XMLink in Perinatology
- Vol. 34 (1) , 9-15
Open AccessAssociation between Metabolic Syndrome at First Trimester and Adverse Pregnancy Outcome: A Cohort Study
Bae JH, et al. Perinatology. 2023 Mar;34(1):9-15. https://doi.org/10.14734/PN.2023.34.1.9